Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pasithea Therapeutics Corp WT (KTTAW)

Pasithea Therapeutics Corp WT (KTTAW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,960 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0180 +11.11%
on 11/20/24
0.0293 -31.74%
on 11/21/24
-0.0075 (-27.27%)
since 10/18/24
3-Month
0.0112 +78.57%
on 08/27/24
0.0982 -79.63%
on 09/27/24
+0.0002 (+1.01%)
since 08/21/24
52-Week
0.0031 +545.16%
on 01/05/24
0.0982 -79.63%
on 09/27/24
+0.0130 (+185.71%)
since 11/20/23

Most Recent Stories

More News
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

KTTA : 3.18 (-0.31%)
KTTAW : 0.0200 (+11.11%)
Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign

Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash...

KTTA : 3.18 (-0.31%)
KTTAW : 0.0200 (+11.11%)
Pasithea Therapeutics Awarded a Drug Development Research Grant

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000 of non-dilutive...

KTTAW : 0.0200 (+11.11%)
KTTA : 3.18 (-0.31%)
Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology...

KTTAW : 0.0200 (+11.11%)
KTTA : 3.18 (-0.31%)
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases --...

KTTA : 3.18 (-0.31%)
KTTAW : 0.0200 (+11.11%)
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology...

KTTAW : 0.0200 (+11.11%)
KTTA : 3.18 (-0.31%)
Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug...

KTTA : 3.18 (-0.31%)
KTTAW : 0.0200 (+11.11%)
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illness...

KTTAW : 0.0200 (+11.11%)
KTTA : 3.18 (-0.31%)
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom

-- Expanding Pasithea Clinics footprint in London --...

KTTAW : 0.0200 (+11.11%)
KTTA : 3.18 (-0.31%)
Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada

-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical...

KTTA : 3.18 (-0.31%)
KTTAW : 0.0200 (+11.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar